Leerink Partners Initiates Coverage On Nektar Therapeutics with Outperform Rating, Announces Price Target of $130
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsInitiationPrice Target
Leerink Partners analyst Will Soghikian initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Outperform rating and announces Price Target of $130.
Leerink Partners analyst Will Soghikian initiates coverage on Nektar Therapeutics (NASDAQ:NKTR) with a Outperform rating and announces Price Target of $130.